Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 4/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | G6PD | P11413 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12608658 | 0.88 | CNR2 (0.44) | CNR2MCHR1ALDH1A1HPGDMAOB | |
| SCHEMBL12608661 | 0.85 | CNR2 (0.44) | CNR2ALDH1A1HPGDMAOBTP53 | |
| SCHEMBL14548984 | 0.85 | HPGD (0.42) | CNR2ALDH1A1HPGDTP53KDM4E | |
| SCHEMBL12608666 | 0.85 | MCHR1 (0.45) | CNR2MCHR1ALDH1A1HPGDKDM4E | |
| SCHEMBL12608637 | 0.83 | CNR2 (0.51) | CNR2ALDH1A1HPGDG6PDHIF1A | |
| SCHEMBL12608663 | 0.83 | CNR2 (0.44) | CNR2MCHR1ALDH1A1HPGDG6PD | |
| SCHEMBL21441047 | 0.82 | CNR2 (0.34) | CNR2MCHR1ALDH1A1HPGD | |
| SCHEMBL12608665 | 0.80 | CNR2 (0.45) | CNR2ALDH1A1HPGDG6PDHIF1A | |
| SCHEMBL12608683 | 0.79 | CNR2 (0.44) | CNR2ALDH1A1HPGDMAOBG6PD | |
| SCHEMBL12608660 | 0.78 | CNR2 (0.43) | CNR2ALDH1A1HPGDG6PDHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190082845-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, INC. | 2017-06-15 | — | — | US | disclosed |
| US-9566265-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2017-02-14 | — | — | US | disclosed |
| US-9566265-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2017-02-14 | — | — | US | disclosed |
| US-20150342927-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20150342927-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, INC. | 2015-12-03 | — | — | US | disclosed |
| US-9108916-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108916-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140303224-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, LLC (US) | 2014-10-09 | — | — | US | disclosed |
| US-8765738-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2014-07-01 | — | — | US | disclosed |
| US-8486697-B2 | Inducing cell death by inhibiting adaptive heat shock response | INCURON, LLC (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486697-B2 | Inducing cell death by inhibiting adaptive heat shock response | INCURON, LLC (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2356093-B1 | Carbazole compounds and therapeutic uses of the compounds | INCURON LLC (RU) | 2013-01-09 | — | — | EP | disclosed |
| US-20110305661-A1 | Carbazole Compounds and Therapeutic Uses of the Compounds | INCURON, INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110305661-A1 | Carbazole Compounds and Therapeutic Uses of the Compounds | INCURON, INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110124104-A1 | INDUCING CELL DEATH BY INHIBITING ADAPTIVE HEAT SHOCK RESPONSE | INCURON, INC. | 2011-05-26 | — | — | US | disclosed |
| US-20110124104-A1 | INDUCING CELL DEATH BY INHIBITING ADAPTIVE HEAT SHOCK RESPONSE | INCURON, INC. | 2011-05-26 | — | — | US | disclosed |
| WO-2010042445-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | CLEVELAND BIOLABS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2009143290-A2 | INDUCING CELL DEATH BY INHIBITING ADAPTIVE HEAT SHOCK RESPONSE | CLEVELAND BIOLABS, INC (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | MALT1, PAICS, BCL9 | CNR2 558/4885MCHR1 4124/4885ALDH1A1 633/4885 |
| US-20150342927-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | MALT1, PAICS, BCL9 | CNR2 558/4885MCHR1 4124/4885ALDH1A1 633/4885 |
| US-20110305661-A1 | Carbazole Compounds and Therapeutic Uses of the Compounds | MALT1, PAICS, TPMT | CNR2 598/4885MCHR1 4281/4885ALDH1A1 589/4885 |
| US-20140303224-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | MALT1, PAICS, BCL9 | CNR2 558/4885MCHR1 4124/4885ALDH1A1 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.